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Abstract: Fungal sepsis is one of the major problems in neonatal and pediatric care unit 
settings. The availability of new diagnostic techniques could allow medical practitioners to 
rapidly identify septic patients and to improve their outcome. The aim of this study was to 
evaluate the performance of the 1→3-β-D-glucan (BDG), individually and in comparison 
with the Candida mannan (CM) antigen, in ten preterm infants and five onco-haematological 
pediatric patients with Candida bloodstream infections already proven by positive culture. 
The serum levels of BDG were >80 pg/mL on the same day as a positive blood culture in 
all examined patients, while CM antigen was negative in the patients with C. parapsilosis 
fungemia and in one further case due to C. albicans. These results suggest that a regular 
monitoring  of  serum  circulating  antigens  (i.e.,  1→3-β-D-glucan)  combined  with  other 
microbiological  and  clinical  information,  may  allow  earlier  and  accurate  diagnosis. 
However, further studies are necessary to confirm its usefulness in routine clinical practice. 
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1. Introduction 
Despite  extensive  research  and  development  in  the  diagnostic  and  therapeutic  fields,  Candida 
bloodstream  infections  (BSI)  remain  an  important  cause  of  morbidity  and  mortality  in  neonatal 
intensive care units (NICU) and in high risk patients, particularly in immunocompromised ones. An 
early diagnosis of invasive fungal disease (IFD) is essential in this population, but the infection is 
difficult to identify because signs and symptoms are often minimal and similar to those of various 
other non-infectious processes. In addition, the diagnosis of candidemia is still primarily limited to 
standard blood cultures, but it is known that traditional methods of microbiological cultures are often 
insensitive or require several days to yield fungi and test their susceptibility to drugs [1,2]. Another 
important  factor  that  can  influence  the  reliability  of  culture  methods  is  previous  prophylaxis  or 
empirical treatments with antifungal drugs. For these reasons, other  laboratory tools were studied. 
Among these, serological tests are difficult to interpret because the circulating antibodies to Candida spp. 
may occur in healthy subjects as a result of commensal colonization of mucosal surfaces. Furthermore, 
their production in the immunocompromised patients varies according to immune status [3]. In these 
complex scenarios, newer diagnostic methods, including biochemical markers, the polymerase chain 
reaction and circulating antigen assays, were made available but are not commonly employed and still 
require standardization and further evaluation. 
The  detection  of  Candida  mannan  antigen  (CM)  has  shown  encouraging  results  in  terms  of 
sensitivity (94.4%) and specificity (94.2%) in neonatal patients with candidemia [4], but its levels in 
blood can be low and the transient nature of antigenaemia requires repetitive sampling. Another serum 
marker recently studied in patients with deep mycoses is 1→3-β-D-glucan (BDG) [5,6], which has 
been included among the relevant diagnostic criteria by the European Organization for Research and 
Treatment of Cancer/Mycoses Study Group (EORTC/MSG) [7]. BDG is a component of the cell wall 
of a wide variety of fungi except for zigomycetes and, to a lesser extent, Cryptococcus spp. [8,9]. 
However, only a few reports specifically describe the clinical relevance of BDG in preterm infants or 
onco-haematological pediatrics with candidemia [10]. Previous data regarding the pediatric population 
derive from a study carried out on healthy children showing BDG levels higher than those reported in 
adults, with a small number of false-positive results [11]. 
The  aim  of  this  study  was  to  evaluate  the  performance  of  the  BDG  test,  individually  and  in 
comparison with CM antigen, in neonatal and pediatric patients with a Candida BSI. 
2. Material and Methods 
We examined fifteen children with Candida BSI already proven by positive culture: ten preterm 
infants (gestational age < 37 weeks) and five onco-haematological children, admitted to the Neonatal 
Intensive Care Unit and to the Haematology Unit of a large University Hospital in Southern Italy. 
In all patients, serum BDG and CM antigens were tested on the same day as the positive blood 
culture and repeated on a sample drawn 24 h later.  
Blood  cultures  were  performed  using  the  lyses  centrifugation  system  (Isolator
®,  DuPont  Co., 
Wilmington, Delaware) and were cultured on Sabouraud agar plates with gentamicin-chloramphenicol 
(Becton-Dickinson, Heidelberg, Germany), incubated at 36 ± 1 °C and examined daily. Int. J. Mol. Sci. 2011, 12                       
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BDG  detection  was  performed  by  colorimetric  assay,  Fungitell  (Associates  of  Cape  Cod  Inc.,  
E. Falmouth, MA, USA), and each serum was tested in triplicate. Serum that was haemolysed, lipemic 
or visually icteric or turbid was not suitable for the assays. BDG levels ≥80 pg/mL were considered as 
positive, ranging from 60 to 79 pg/mL as indeterminate, <60 pg/mL as negative. 
CM  antigen  was  assayed  using  a  commercial  sandwich  enzyme-linked  immunoassay,  Platelia 
Candida Ag (BioRad, Marnes La Coquette, France). Antigen values ≥0.5 ng/mL were considered as 
positive, ranging from 0.25 to 0.49 ng/mL as intermediate and <0.25 ng/mL as negative. 
Both tests were performed according to the manufacturer's instructions. 
As  negative  controls,  15  hospitalized  patients  (10  preterm  infants,  and  5  onco-haematological 
children) without any clinical evidence of fungal infection (i.e., fever, increased C-reactive protein 
levels) and with negative blood culture was tested for BDG and CM antigens. 
3. Results 
The  demographic/clinical  characteristics  of  patients  with  candidemia  and  results  of  antigens 
research are summarized in Table 1. 
Table 1. Clinical features, culture data and values of 1→3-β-D-glucan (BDG) and Candida 
mannan (CM) antigen for 15 patients, timing of documented candidemia. 
Patient 
no. 
Age/Gender 
Underlying 
condition 
Isolates  BDG (pg/mL)  CM (ng/mL) 
1  25 days/M  ELBW (825 g)  C. albicans  >523  1.70 
2  75 days/M  ELBW (535 g)  C. parapsilosis  >523  <0.25 
3  25 days/M  VLBW (1065 g)  C. albicans  276  1.88 
4  20 days/M  VLBW (1010 g)  C. albicans  312  1.60 
5  103 days/M  VLBW (1145 g)  C. albicans  >523  1.53 
6  9 days/F  VLBW (1200 g)  C. parapsilosis  >523  <0.25 
7  11 days/F  VLBW (1255 g)  C. parapsilosis  >523  <0.25 
8  120 days/M  LBW (1600 g)  C. albicans  190  1.37 
9  120 days/M  LBW (1570 g)  C. albicans  230  1.05 
10  145 days/M  LBW (1600 g)  C. glabrata  183  1.50 
11  13 years/M  NHL  C. albicans  98  <0.25 
12  11 years/M  ALL  C. albicans  100  1.15 
13  5 years/F  AML  C. parapsilosis  310   <0.25 
14  2 years/F  ALL  C. parapsilosis  222   <0.25 
15  2 years/M  ALL  C. lusitaniae  135   0.71 
BDG, (1→3) β-D-glucan; CM, Candida mannan; M,  male; F, female; ELBW, Extremely Low 
Birth Weight (≤1000 g); VLBW, Very Low Birth Weight (1001–1500 g); LBW, Low Birth Weight 
(1501–2500  g);  ALL,  acute  lymphoid  leukemia;  AML,  acute  myeloid  leukaemia;  NHL,  
non-Hodgkin’s lymphoma. 
Ten  out  of  the  15  patients  were  pre-term  infants:  two  Extremely  Low  Birth  Weight  
(ELBW, <1000 g), five Very Low Birth Weight (VLBW, between 1001 and 1500 g) and three Low 
Birth Weight (LBW, between 1501 and 2500 g). Overall, six patients developed a BSI caused by  
Candida albicans, three by Candida parapsilosis and one by Candida glabrata. Int. J. Mol. Sci. 2011, 12                       
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On the same day as the positive blood culture, the BDG values were >80 pg/mL in all ten neonates 
with Candida BSI, while the CM antigen values were >0.5 ng/mL only in seven infants (six with  
C. albicans and one with C. glabrata BSI). The remaining three infants with C. parapsilosis BSI  
were negative. 
Regarding the onco-haematological pediatric patients (three affected by acute lymphoid leukaemia, 
one  by  acute  myeloid  leukaemia  and  one  by  non-Hodgkin’s  lymphoma),  all  five  children  had  
BDG >80 pg/mL on the same day as the positive blood culture, while the CM antigen resulted positive 
only in two children (one with C. albicans and one with Candida lusitaniae fungemia). The remaining 
three children (two with C. parapsilosis and one C. albicans BSI) were negative. 
These results were confirmed in all the samples drawn 24 h after the first one. 
The BDG and Candida mannan tests were always negative in all control patients.  
4. Discussion 
The aim of this  study  is to evaluate the presence of circulating antigens (1→3-β-D-glucan  and 
Candida mannan) in the serum of neonatal and pediatric patients with BSI on the same day as the 
notification of yeasts in their blood culture. Although the number of enrolled patients was low, we 
consider it interesting to underline the constant correspondence of the BDG antigen test results in  
all  fifteen  children  with  the  timing  of  the  positive  blood  culture,  even  when  the  mannan  antigen 
resulted negative. In fact, in all our patients with C. parapsilosis BSI, mannan antigen was negative 
according to literature data that report a very low sensitivity of Platelia Candida antigen test in patients 
with  C.  parapsilosis  infection,  probably  because  of  the  lower  amount  of  mannan  released  by  
this  species  [4,12].  The  fact  that  this  assay  was  negative  in  each  patient  with  C.  parapsilosis 
candidemia suggests that it could not be a useful surrogate marker in this population. This is a real  
problem,  because C. parapsilosis representing the second  most common  species  isolated from the  
pediatric population [13]. 
However,  even  considering  the  greater  sensitivity  of  the  Platelia  Candida  antigen  test  for  
infections caused by C. albicans [14], this data could not be confirmed in any of our patients with  
C.  albicans  BSIs.  Most  notably,  one  out  of  the  five  onco-haematological  pediatric  patients  was 
severely immunocompromised and had a long complicated course of the disease in rapid progression 
with severe complications but favorable resolution of C. albicans BSI. In this patient, the BDG test 
was positive on the same day as the blood culture, but a negative mannan antigen test was observed in 
both serum samples tested in two consecutive days under study. For these reasons, taking into account 
also the low sensitivity of blood cultures for Candida detection, especially in neonatal patients [3], and 
the  rapid  clearance  of  mannan  antigen  from  the  blood  [15],  a  positive  BDG  test  could  raise  the 
suspicion of fungal disease even when the mannan antigen test and/or blood cultures are negative.  
Our data are in agreement with Mularoni et al. [10] who reported high plasmatic levels of BDG 
(>523 pg/mL) in serum of four children with documented IFD. Interestingly, in a retrospective study 
of 27 patients with candidemia (three subjects were pediatric patients), Alam et al. [16] evaluated the 
diagnostic value of BDG individually and in comparison with other disease markers (Candida mannan 
and anti-mannan antibodies), suggesting that the combination of two or more diagnostic assays could 
help to enhance the sensitivity for diagnosis of candidemia.  Int. J. Mol. Sci. 2011, 12                       
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In the light of the constant positivity of BDG antigen test in our patients with fungemia, it should be 
considered that the glucan is ubiquitous in the environment, so some medical sources of BDG can lead 
to  a  false  positive  assay  result  in  the  absence  of  IFI:  dialysis  membranes  and  filters  made  from 
cellulose, cotton gauze employed during surgery, specific fractionated blood products such as serum 
albumin  and  immunoglobulins  are  reported  to  contain  BDG.  Moreover,  there  are  other  potential 
reasons for false positive BDG reactions: exposure to antitumor polysaccharides such as lentinam, 
polysaccharide  K  and  schizophyllan  which  are  derived  from  different  species  of  mushrooms,  and 
treatment  with  certain  parenteral  antimicrobials  [17–19].  We  considered  these  possibilities  in  the 
course of the study, and the interpretation of our results was made in view of all these circumstances. 
The clinical setting of our patients did not appear to be significant and consequently, we can rule out 
the possibility of such interferences. 
In  a  recent  study  Mokaddas  et  al.  [20]  have  reported  that  some  pediatric  patients  colonized  
with Candida spp. had high levels of BDG. We are able to exclude also this possible interference, 
because in our hospital a weekly microbiological surveillance is carried out in various anatomic sites  
(i.e.,  nose,  oropharynx,  intestine,  vagina)  of  patients  at  high  risk  for  fungal  disease.  No  fungal 
colonization was detected in all studied patients.  
5. Conclusions 
We are aware that the this study presents some limitations (i.e., the lack of constant monitoring of 
BDG  levels),  but  we  aimed  to  evaluate the  presence  of  BDG  on  the  same  day  of  candidemia  to 
establish the role of this assay in the diagnosis of this disease in pediatric population. We think the 
research of BDG cannot entirely replace the standard diagnostic approaches, but a regular monitoring 
of this circulating antigens over time, combined with other microbiological and clinical information, 
may allow earlier and accurate diagnosis in this setting patients and minimize the inappropriate use of 
drugs.  In  this  context,  the  goal  of  this  preliminary  study  is  to  provide  a  platform  for  mycologist 
scientists to promote and discuss the design of future trials focused to elucidate this issue. 
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